Print | Share | Contact Us | Search:

A Passionate Commitment to Rare Disorders

Dr. Nader VideoNPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The company’s lead product, Gattex® (U.S.)/Revestive® (EU) 0.05 mg/kg/b (teduglutide [rDNA origin]) for injection for subcutaneous use is approved for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. NPS has also developed Natpara® (rhPTH [1-84]) for the treatment of hypoparathyroidism and submitted its Biologic License Application to the U.S. Food and Drug Administration in October 2013. NPS's earlier stage pipeline includes NPSP795, a calcilytic compound with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia (ADH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates.

Click here for more NPS News.
     Calendar of Events


Gattex logo

Click here for full prescribing information for Gattex

For more information, please visit